Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 27 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Sana Biotechnology, Inc. | 10,667,387 | reported | 08 Feb 2024 | tx 3+1,818,181 |
| Neumora Therapeutics, Inc. | 80,000 | reported | 27 May 2026 | tx 48+23,659,917−17,588,376 |
| Gossamer Bio, Inc. | 35,000 | reported | 08 Jun 2023 | tx 13+8,191,416−36,251,633 |
| Vir Biotechnology, Inc. | 25,404 | reported | 21 May 2020 | tx 9+28,276,511−27,222,219 |
| Sienna Biopharmaceuticals, Inc. | 25,000 | reported | 30 May 2019 | tx 14+5,839,183−3,633,068 |
| Unity Biotechnology, Inc. | 25,000 | reported | 24 Jun 2021 | tx 14+10,124,312−10,008,634 |
| Scholar Rock Holding Corp | 21,071 | reported | 29 May 2025 | tx 24+2,806,568−7,827,176 |
| Beam Therapeutics Inc. | 16,532 | reported | 06 Jun 2023 | tx 29+8,288,906−10,643,039 |
| Metacrine, Inc. | 16,500 | reported | 24 May 2021 | tx 11+2,957,003−2,710,503 |
| Boundless Bio, Inc. | 16,000 | reported | 23 Jun 2025 | tx 14+2,668,159−2,425,721 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 27 May 2026 | GRANT_AWARD | Neumora Therapeutics, Inc. | 80,000 | 0.00 USD | deriv |
| 13 Nov 2025 | OTHER | Metsera, Inc. | 18,503,128 | — | |
| 13 Nov 2025 | OTHER | Metsera, Inc. | 7,523,682 | — | |
| 13 Nov 2025 | OTHER | Metsera, Inc. | 8,313,680 | — | |
| 13 Nov 2025 | OTHER | Metsera, Inc. | 17,070,904 | — | |
| 13 Nov 2025 | OTHER | Metsera, Inc. | 2,688 | — | |
| 13 Nov 2025 | OTHER | Metsera, Inc. | 16,125 | — | deriv |
| 13 Nov 2025 | GRANT_AWARD | Metsera, Inc. | 2,688 | — | deriv |
| 13 Nov 2025 | OTHER | Metsera, Inc. | 148,953 | — | deriv |
| 27 Oct 2025 | PURCHASE | Neumora Therapeutics, Inc. | 1,915,700 | 2.61 USD | |
| 23 Jun 2025 | GRANT_AWARD | Boundless Bio, Inc. | 16,000 | 0.00 USD | deriv |
| 29 May 2025 | SALE | Scholar Rock Holding Corp | 1,000 | 29.24 USD | |
| 29 May 2025 | SALE | Scholar Rock Holding Corp | 4,400 | 29.83 USD | |
| 28 May 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 28,571 | — | deriv |
| 28 May 2025 | OTHER | Neumora Therapeutics, Inc. | 46,455 | — | deriv |
| 28 May 2025 | OTHER | Neumora Therapeutics, Inc. | 28,571 | — | deriv |
| 28 May 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 46,455 | — | deriv |
| 28 May 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 80,000 | 0.00 USD | deriv |
| 22 May 2025 | GRANT_AWARD | Scholar Rock Holding Corp | 7,632 | 0.00 USD | |
| 22 May 2025 | GRANT_AWARD | Scholar Rock Holding Corp | 9,206 | 0.00 USD | deriv |
| 20 May 2025 | GRANT_AWARD | Metsera, Inc. | 16,125 | 0.00 USD | deriv |
| 13 Feb 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 28,571 | — | deriv |
| 13 Feb 2025 | GRANT_AWARD | Neumora Therapeutics, Inc. | 46,455 | — | deriv |
| 13 Feb 2025 | OTHER | Neumora Therapeutics, Inc. | 28,571 | — | deriv |
| 13 Feb 2025 | OTHER | Neumora Therapeutics, Inc. | 46,455 | — | deriv |
3 purchases reported after at least 12 months of silence — most recent on 19 Sept 2023.